艾拉戈利治疗对子宫内膜异位症相关中重度疼痛女性疲劳的影响
这项随机双盲多中心安慰剂对照III期试验纳入860例子宫内膜异位症相关中重度疼痛女性,比较艾拉戈利150mg每日一次、200mg每日两次与安慰剂的疲劳改善效果。6个月时艾拉戈利两组PROMIS疲劳T评分较基线下降均显著优于安慰剂。
要点
- 基线时54%–74%的中重度疼痛患者报告有相当程度的疲劳相关问题。
- 6个月时艾拉戈利150mg每日一次和200mg每日两次组疲劳T评分分别下降2.21和5.90,均显著优于安慰剂。
- 痛经、非经期盆腔痛和性交痛达到临床有意义缓解者疲劳评分下降更显著。
核心结论
- 在子宫内膜异位症相关中重度疼痛女性中,艾拉戈利显著降低疲劳水平。
研究设计与样本
- 随机、双盲、多中心、安慰剂对照III期试验,共860例女性接受艾拉戈利或安慰剂治疗。
- 干预为艾拉戈利150mg每日一次口服、艾拉戈利200mg每日两次口服或安慰剂。
主要发现
- 基线时54%–74%的中重度子宫内膜异位症相关疼痛女性报告疲劳相关问题为「相当多」或「非常多」,比例随所问问题而异。
- 6个月时艾拉戈利150mg每日一次组疲劳程度降至29%–43%,200mg每日两次组降至14%–29%,安慰剂组为35%–50%。
- 6个月时艾拉戈利150mg每日一次和200mg每日两次组疲劳T评分分别下降2.21和5.90,较安慰剂显著。
- 痛经、非经期盆腔痛和性交痛达到临床有意义「缓解」的患者疲劳评分分别下降7.31、6.62和4.31,显著大于未缓解者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the efficacy of elagolix, an oral GnRH antagonist, for the reduction of fatigue in women with moderate or severe endometriosis-associated pain. DESIGN: Randomized, double-blind, multicenter, placebo-controlled phase III trial. SETTING: Clinics. PATIENT(S): A total of 860 women treated with elagolix or placebo. INTERVENTION(S): Women received either elagolix at 150 mg daily (QD) orally, elagolix at 200 mg twice daily (BID) orally, or placebo. MAIN OUTCOME MEASURE(S): Change from baseline to month 1, 3, and 6 visits, in Patient-Reported Outcomes Measurement Information System (PROMIS) Fatigue Short Form 6a questionnaire T-scores. RESULTS(S): At baseline, 54%-74% of women with moderate to severe pain associated with endometriosis reported having fatigue-related issues "quite a bit" or "very much," depending on the question asked. Fatigue extent was reduced to 29%-43% and 14%-29% for women treated with elagolix at 150 mg QD and 200 mg BID, respectively, at 6 months, compared with 35%-50% with placebo. The resultant decrease in fatigue T-scores was significant after elagolix treatment compared with placebo at 6 months, with changes of -2.21 and -5.90 with elagolix at 150 mg QD and 200 mg BID, respectively. Significant reduction in fatigue scores were observed among patients reporting clinically meaningful response "reduction" in dysmenorrhea, nonmenstrual pelvic pain, and dyspareunia (-7.31, -6.62, and -4.31, respectively) compared with nonresponders. CONCLUSION(S): In women with moderate to severe endometriosis related pain, elagolix significantly reduces fatigue levels.
引用
- Surrey ES, Soliman AM, Agarwal SK, et al. Impact of elagolix treatment on fatigue experienced by women with moderate to severe pain associated with endometriosis. Fertil Steril. 2019. PMID: 30992150. doi:10.1016/j.fertnstert.2019.02.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。